Thank you to everyone who stopped by Booth 1278 to connect with the $BIAF team during #CHEST2026! We’ve appreciated the conversations around #CyPathLung and noninvasive lung cancer risk assessment.
There’s still another opportunity to connect with us! Join $BIAF CMO Dr. Gordon H. Downie for a Learning Theater presentation on CyPath® Lung testing for early lung cancer diagnosis and pulmonary nodule risk stratification.
📷 Learning Theater 4
📷 Oct. 21 | 12:30–1:15 p.m. MT
Today at #CHEST2026, bioAffinity Technologies presents “Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma.”
Poster 3071 | Original Investigation / Allergy-Airway
1:45–2:30 p.m. MT | Phoenix Convention Center
Details: bit.ly/4yPC6eW $BIAF
Diagnosing lung cancer can involve several tools, and each provides a different kind of information. CyPath® Lung analyzes cells in sputum and can be used alongside imaging, PET, bronchoscopy and biopsy to help inform nodule evaluation. Learn more: cypathlung.com/ $BIAF
bioAffinity Technologies is at #CHEST2026! Visit the team at Booth 1278 throughout the conference to learn more about #CyPathLung and the Company’s work in lung cancer diagnostics.
We look forward to connecting with you. $BIAF
ICYMI, bioAffinity Technologies will present new research at #CHEST2026 on measuring lung inflammation and biologic drug targets in sputum, supporting development of tests for asthma and COPD.
Read the announcement: bit.ly/4yPC6eW $BIAF
bioAffinity Technologies will sponsor a Learning Theater presentation at #CHEST2026 led by Chief Medical Officer Dr. Gordon Downie on using #CyPathLung for early lung cancer detection and pulmonary nodule risk stratification.
Read more: bit.ly/4eyGSoN $BIAF
An indeterminate lung nodule can leave clinicians weighing whether to monitor or move forward with biopsy. In this case, a #CyPathLung result supported monitoring, and follow-up CT showed the nodule remained stable. Learn more: cypathlung.com/ $BIAF
bioAffinity Technologies will present new research at #CHEST2026 on measuring lung inflammation and drug targets in sputum.
The findings support development of noninvasive tests for asthma and COPD using the Company’s flow cytometry + AI platform. bit.ly/4yPC6eW $BIAF
We join the world in wishing Pope Leo XIV all the best for his health and well-being.
The recent news of the Pope's lung nodule highlights the importance of lung cancer screening and early diagnosis.
#PopeLeo #lungcancer #lungnodule #screeningsaveslives #CyPathLung
🧵Finding lung cancer early can save lives.
That makes screening essential. But when a screening result comes back positive, patients and physicians still need to know what that result really means. $BIAF (1/4)
🪡 That uncertainty can come with anxiety, added cost and invasive procedures that may ultimately prove unnecessary.
A patient-friendly, noninvasive way to gather more information could make the next step easier for both patients and physicians. $BIAF (3/4)
🪡 #CyPathLung is designed to be used after a positive LDCT to provide additional information about the likelihood of lung cancer and help physicians make more informed follow-up decisions.
cypathlung.com/ $BIAF (4/4)
This week, $BIAF VA Pulmonary Sales Executive Matt McCumber represented bioAffinity Technologies at the Government Expo at the San Diego VAMC, connecting with clinicians and federal healthcare decision-makers about #CyPathLung and its role in veteran healthcare.
bioAffinity Technologies $BIAF received a Notice of Allowance from the Japan Patent Office covering #CyPathLung and its AI-built algorithm for predicting lung cancer likelihood.
It will be the fifth patent protecting the noninvasive test in Asia.
Read: bit.ly/4dXM8SE
🧵 #CyPathLung sales grew more than 100% through Q3 2026 compared with the same period last year.
The growth reflects both an expanding physician base and increased utilization among physicians already using the test. $BIAF (1/4)
Existing users are also increasing their use of #CyPathLung
Physicians who ordered CyPath® Lung in 2025 increased utilization by nearly 50% through Q3 2026, adding another source of growth as use expands in clinical practice. (3/4)
Together, increased physician adoption and deeper utilization among existing users are contributing to continued commercial growth for CyPath® Lung.
ICYMI, read the latest update: bioaffinitytech.com/bioaffin… $BIAF (4/4)